DONATE
DONATE

Policy and Advocacy News 3

Policy and Advocacy News

1 | 2 | 3

  • Monkeypox: Time Is of the Essence

    amfAR and the O’Neill Institute have issued a policy brief on monkeypox urging action to prevent further spread of the disease.

  • amfAR at AIDS 2022

    Researchers from amfAR and the foundation’s partners will present on community-led HIV programming at the 24th International AIDS Conference

  • The Supreme Court’s Calamitous Decision

    amfAR condemns the repeal of Roe v. Wade, which denies people the right to abortion and creates barriers to HIV and other sexual health services.

  • Response to ICAP’s Critique of “Blinded by Our Own Data”

    amfAR’s Public Policy Office responds to ICAP’s critique of its report on PEPFAR’s HIV recency testing program, “Blinded by Our Own Data”.

  • Blinded By Our Own Data

    PEPFAR’s recency testing-based approach to identify and target HIV transmission “hot-spots” suffers from severe limitations, says amfAR in new report.

  • In Memoriam: Urvashi Vaid

    amfAR mourns the passing of attorney Urvashi Vaid, an LGBTQ activist dedicated to civil rights, anti-war efforts, health justice, and HIV/AIDS.

  • amfAR’s Greg Millett Presents at Smithsonian World AIDS Day Event

    amfAR vice president and director of public policy Greg Millett took part in a World AIDS Day program sponsored by the Smithsonian’s National Museum of Natural History on December 3, 2020. Millett spoke in a segment covering laws and policies affecting people with HIV.

  • Biden Releases Updated National HIV/AIDS Strategy

    At a World AIDS Day event at the White House, President Biden announced the release of an updated National HIV/AIDS Strategy and recommitted the United States to ending AIDS as a public health threat by 2030.

  • Stark Inequities Continue to Undermine U.S. HIV Response

    Unequal access to prevention and care, stigma drive worrying trends for Black and Latino gay men.

  • FDA Approves Long-Acting Injectable to Treat HIV

    A long-acting-acting HIV treatment consisting of two shots monthly has been approved by the U.S. Food & Drug Administration (FDA) for adults with suppressed virus currently on a stable antiretroviral regimen.

  • amfAR’s Greg Millett Presents on 40th Anniversary of HIV/AIDS

    amfAR vice president and director of public policy Greg Millett took part in a virtual webinar and conversation with senior federal officials and community leaders on the 40th anniversary of HIV/AIDS on Tuesday, June 15, 2021. Greg discussed how HIV has changed the world, and similarities between COVID-19 and HIV.

  • U.S. Sees Progress on HIV, Room for Improvement

    A series of reports released by the Centers for Disease Control and Prevention (CDC), May 27, show “hopeful signs of progress” but point to some areas in which progress continues to lag. The reports, which use CDC surveillance data, all cover the five-year period 2015 to 2019.

  • A Neglected Population: Transgender Inclusion in National HIV Plans

    Worldwide, transgender people are disproportionately impacted by HIV, but historically overlooked in HIV National Strategic Plans (NSPs).

  • People Living with HIV Should Be Prioritized for Coronavirus Vaccine

    As coronavirus vaccine distribution gathers pace across the U.S., there is limited consensus and some confusion as to which populations should be prioritized for the vaccine.

  • amfAR Study Wins Elsevier Atlas Award

    Study was first to rigorously quantify effects of coronavirus pandemic in Black communities nationally.

1 | 2 | 3